Therapeutic drug monitoring

Global Therapeutic Drug Monitoring Clinical Pipeline Report 2023: Analysis by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024
Pharmaceutical, Health, Medical Supplies, Therapeutic drug monitoring, Perspiration, Urine, Medical device

The "Therapeutic Drug Monitoring Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Therapeutic Drug Monitoring Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • 'Therapeutic Drug Monitoring Pipeline Report' provides comprehensive information about the Therapeutic Drug Monitoring pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Therapeutic drug monitoring tests include reagents and test kits intended to measure different types of therapeutic drugs from samples ranging from serum/blood, urine, hair and sweat.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    In-depth analysis of the product's current stage of development, territory and estimated launch date

DoseMe Adds Cefepime to Its Model-informed Precision Dosing Platform

Retrieved on: 
Monday, December 4, 2023
Technology, Biotechnology, FDA, Health, Pharmaceutical, Other Science, University, Research, Software, Infectious Diseases, Education, Health Technology, Science, Data Management, Hospice and palliative medicine, Neutropenia, Genetically modified bacteria, Cefepime, BCPS, TDM, Pneumonia, Doctor of Pharmacy, Risk, Fungal infection, Serum, Patient, Infection, Midwestern University, Pharmacokinetics, University of Illinois Chicago, Kidney, Owen Scheetz, Bacteria, Creatinine, Neurotoxicity, EGFR, Bias, Postgraduate education, Skin, Therapeutic drug monitoring, Pharmaceutical industry, Pharmacology, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the availability of its Cefepime model.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the availability of its Cefepime model.
  • His research continues to highlight three keys to infectious disease monitoring - real time beta lactam monitoring, therapeutic drug monitoring and precision dosing.
  • “Similar to many beta lactam treatments, Cefepime displays a large amount of variability between patients and having DoseMeRx enables precision dosing,” stated Scheetz.
  • Greater recognition of the benefits of Model-informed Precision Dosing (MIPD) software for enhancing TDM and dosing precision necessitates thorough validation of models and reassessment of current workflows.

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety

Retrieved on: 
Wednesday, November 8, 2023
Signal, DEC, US, Product management, Data, Disulfiram-like drug, ICSR, Comparison, EMR, Noise, AE, Patient safety, Therapeutic drug monitoring, Patient, Instrumentation, Pharmaceutical industry, Medical imaging, Safety, EU

BOSTON, Nov. 8, 2023 /PRNewswire/ -- ArisGlobal, creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology's ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications.

Key Points: 
  • A foundational and comparative study of ArisGlobal's LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives).
  • She commented: "Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug's addressable market.
  • "But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality.
  • ArisGlobal's CEO, Mike Gordon, commented, "Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring."

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety

Retrieved on: 
Wednesday, November 8, 2023
Signal, DEC, US, Product management, Data, Disulfiram-like drug, ICSR, Comparison, EMR, Noise, AE, Patient safety, Therapeutic drug monitoring, Patient, Instrumentation, Pharmaceutical industry, Medical imaging, Safety, EU

BOSTON, Nov. 8, 2023 /PRNewswire/ -- ArisGlobal, creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology's ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications.

Key Points: 
  • A foundational and comparative study of ArisGlobal's LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives).
  • She commented: "Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug's addressable market.
  • "But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality.
  • ArisGlobal's CEO, Mike Gordon, commented, "Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring."

ProciseDx Expands Intellectual Property Portfolio with Purchase of Two US Therapeutic Drug Monitoring Patents

Retrieved on: 
Wednesday, October 18, 2023
Laboratory, FDA, C-reactive protein, Infliximab, Family, TNF, Doctor of Philosophy, Inflammatory bowel disease, Beth Israel Deaconess Medical Center, Antibody, Adalimumab, IBD, Patient, TDM, Therapeutic drug monitoring, CRP, SAN, Pharmaceutical industry, MD

SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.

Key Points: 
  • SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.
  • 11,119,096 "Universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug antibodies in samples" and US Patent No.
  • "We believe these patents as well as our existing intellectual property forms a solid foundation for our path forward in expanding our reach in therapeutic drug monitoring of biological drugs," said Larry Mimms, PhD, CEO of ProciseDx.
  • ProciseDx received FDA clearance for the ProciseDx analyzer and first immunoassay for C-Reactive protein (CRP) in November, 2022.

ProciseDx Announces the First FDA-cleared Therapeutic Drug Monitoring Tests for Biologic Drugs, Humira®, Remicade®, and their Biosimilars

Retrieved on: 
Tuesday, October 3, 2023
Therapeutic drug monitoring, Serum, Doctor of Philosophy, Hospital, MD, Patient, CRP, American College, TDM, University, Infliximab, Laboratory, Joshua Casteel, FDA, Workflow, Adalimumab, Energy, Ulcerative colitis, Crohn's disease, SAN, IBD, ADL, Pharmaceutical industry, Medical device

SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has been granted de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira® and biosimilar Amgevita®) and infliximab (Remicade® and biosimilars Inflectra® and Renflexis®).

Key Points: 
  • SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has been granted de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira® and biosimilar Amgevita®) and infliximab (Remicade® and biosimilars Inflectra® and Renflexis®).
  • ProciseDx expects to commercialize these first FDA-cleared infliximab and adalimumab drug monitoring tests in Q4 2023.
  • The tests can be performed using serum and take only 5 minutes to obtain a quantitative result.
  • "The ProciseDx platform will change that, with a simple workflow producing a reliable quantitative measurement in 5 minutes or less.

PrecisePK's Bayesian Precision Dosing Solutions Gain Trust of Premier Health System- Setting the Gold Standard for Clinicians in South America

Retrieved on: 
Monday, October 2, 2023
Vancomycin, Partnership, Therapeutic drug monitoring, Software, Teaching, Evidence-based practice, HPL, Associate, Student, Pharmacist, Hospital, Patient, SAN, Medicine, Health, TDM, Pharmacology, Pharmaceutical industry, Nursing, Pharmacy, Chemistry

This 2-year collaboration with Clínica Andes Salud Concepción marks another significant stride toward elevating the standard of clinical outcomes and patient experiences in South America.

Key Points: 
  • This 2-year collaboration with Clínica Andes Salud Concepción marks another significant stride toward elevating the standard of clinical outcomes and patient experiences in South America.
  • In conclusion, PrecisePK's unwavering dedication to advancing global healthcare through precision medicine in South America stands as a testament to the transformative power of Bayesian Precision Dosing solutions.
  • With influential partnerships in clinical settings and a profound impact on academic progress, PrecisePK has set a gold standard for clinicians and researchers alike.
  • By adopting these model-informed precision dosing solutions, Chilean hospitals continue to ensure medication safety and promote adherence to responsible antibiotic stewardship principles.

DoseMe Selected as a Pharma 2023 Innovation Award Winner

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Index, Therapeutic drug monitoring, Clinical trial, Pharmacokinetics, Endeavor Business Media, Risk, Toxic leukoencephalopathy, ADE, Environment, TDM, Software, Pharmaceutical industry, List of things named after Thomas Bayes, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) today announced its DoseMe Analytics platform was named a winner of the Pharma Innovation Awards.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) today announced its DoseMe Analytics platform was named a winner of the Pharma Innovation Awards.
  • Pharma Manufacturing , an Endeavor Business Media brand, annually recognizes technologies contributing to advancements in risk reduction, product quality improvement, and manufacturing efficiency.
  • The Pharma Innovation Awards are a tribute to those who listen to the needs of the market and their customers, and as a result, have distinguished themselves as leaders in pharma equipment and technology.
  • “We are honored to be selected along with 12 other incredibly valuable tools that help pharma companies to develop innovative, lifesaving medicines,” stated Paul Edwards, CEO of DoseMe.

An Innovative Solution to Tackling the Escalating US Drug Crisis

Retrieved on: 
Thursday, August 31, 2023
Therapeutic drug monitoring, Face, Public, Support, Multimedia, Privacy, Doctor of Philosophy, PULSE, Drug-related deaths in the United Kingdom, Synthetic, Medical device, Vaccine, Management, Online shopping

CARLSBAD, Calif., Aug. 31, 2023 /PRNewswire-PRWeb/ -- In the wake of an escalating drug crisis, a consortium of experts, including Corina J Shtir, PhD., Rockwell Herron, Christopher Nielsen, Paul Scott, Jonathan Martin, and John Shtir, releases a groundbreaking whitepaper titled "Facing the Drug Pandemic Problem in the United States: An Epidemiological Approach to Assess Drug Use and Support Preventive Measures." This comprehensive study exposes the alarming rise in drug-related deaths and introduces a cutting-edge technological approach to counter the crisis.

Key Points: 
  • A consortium of experts is addressing the escalating US drug crisis, unveiling a technological approach to counter it.
  • This comprehensive study exposes the alarming rise in drug-related deaths and introduces a cutting-edge technological approach to counter the crisis.
  • "In the face of a growing and complex drug crisis, we need a dynamic and data-driven approach that can adapt rapidly."
  • The whitepaper addresses the gravity of the drug crisis and introduces the PULSE platform as a potent weapon against drug poisoning.

A.C. Camargo Cancer Center Harnesses the Power of DoseMe Precision Dosing Platform to Substantially Reduce Toxicity and Kidney Injuries

Retrieved on: 
Wednesday, August 30, 2023
Managed Care, Software, Research, Other Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Hospitals, Health Technology, Clinical Trials, Science, Health, BCPS, PM, Doctor of Pharmacy, University, Education, Evidence-based medicine, Post, Serum, Acute kidney injury, Survival, Infection, Cancer, International Association, Rehabilitation, Clinical endpoint, Doctor of Philosophy, ECCMID, Vancomycin, Patient, Collection, Nursing, Therapeutic drug monitoring, Diagnosis, Hospital, Yale Cancer Center, TDM, Pharmaceutical industry, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.
  • A.C. Camargo is an integrated Cancer Center for diagnosis, treatment, education and research.
  • Since its inception in 1953, A.C. Camargo has made significant and ongoing contributions to the fight against cancer and it is recognized internationally as a reference institution.
  • "DoseMe is critical to our team's ability to access real-time data and continue to deliver on our promise of customized care for every single patient."